Perrigo Company plc (PRGON.MX)
| Previous Close | 686.00 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 687.00 - 687.00 |
| 52 Week Range | 687.00 - 687.00 |
| Volume | |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -16.49 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswirePerrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that pharmaceutical company Esteve Healthcare, S.L. ("ESTEVE") has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to €275 million, consisting of an upfront cash payment of €190 million and up to €85 million in potential earnout payments based on the Rare Diseases business achieving certain sales milestones.
- PR Newswire
Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2024 financial results on Tuesday, May 7th, 2024, and host a conference call beginning at 8:30 A.M. (EDT).
PR NewswireOpill and WNBA Team Up for Groundbreaking Partnership
Today, Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced that Opill® — the first-ever daily birth control pill available without a prescription in the U.S. — and the Women's National Basketball Association (WNBA) have entered a multi-year partnership that focuses on building confidence, strength and health equity, all of which closely align with both organizations' core priorities.
